{"filing":{"accession_number":"0001193125-26-257394","cik":"0001623526","ticker":"STOK","company_name":"Stoke Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d15052d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/d15052d8k.htm"},"events":[{"id":6807,"run_id":5964,"accession_number":"0001193125-26-257394","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of Stoke Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026, including voting outcomes for three proposals: election of three Class I directors (G. Clare Kahn, Adrian Krainer, and Julie Anne Smith), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (Shares For, Against, Withheld, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures under Item 5.07.","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4334,"accession_number":"0001193125-26-257394","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Stoke Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026, including voting outcomes for three proposals: election of three Class I directors (G. Clare Kahn, Adrian Krainer, and Julie Anne Smith), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (Shares For, Against, Withheld, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:31.349486+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4334,"accession_number":"0001193125-26-257394","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Stoke Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026, including voting outcomes for three proposals: election of three Class I directors (G. Clare Kahn, Adrian Krainer, and Julie Anne Smith), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (Shares For, Against, Withheld, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:31.349486+00:00","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-06-04"}]}